Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2022; 10(31): 11240-11251
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11240
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11240
Intestinal microbiota in the treatment of metabolically associated fatty liver disease
Ji-Shuai Wang, Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Jin-Chun Liu, Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China
Author contributions: Wang JS wrote original draft and data curation; Liu JC contributed the conceptualization.
Supported by the Scientific and Technological Achievements Transformation Guidance Special of Shanxi Province in China , No. 201904D131030 .
Conflict-of-interest statement: All authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jin-Chun Liu, MD, Chief Doctor, Full Professor, Department of Gastroenterology, The First Hospital of Shanxi Medical University, No. 85 Jiefangnan Road, Taiyuan 030001, Shanxi Province, China. zxr610624@163.com
Received: July 30, 2022
Peer-review started: July 30, 2022
First decision: September 2, 2022
Revised: September 7, 2022
Accepted: September 27, 2022
Article in press: September 27, 2022
Published online: November 6, 2022
Peer-review started: July 30, 2022
First decision: September 2, 2022
Revised: September 7, 2022
Accepted: September 27, 2022
Article in press: September 27, 2022
Published online: November 6, 2022
Core Tip
Core Tip: Recent animal studies and Clinical researches have placed the gut microbiota as a potentially important player in the pathogenesis of metabolically associated fatty liver disease (MAFLD). It is logical to target the gut microbiota to develop new strategies for MAFLD therapy. In addition, we assessed the therapeutic potential of intestinal microbiota manipulation for treating MAFLD and discussed the specific doses and duration of use can provide more help for clinicians in choosing treatment options.